Translational Drug Development (TD2)

Today, on World Pancreatic Cancer Day, we honor the patients, families, and researchers dedicated to advancing the fight against one of the most challenging cancers. Pancreatic cancer remains one of the leading causes of cancer-related deaths worldwide, with an urgent need for innovative treatments. At TD2, our team is proud to support groundbreaking research aimed at improving outcomes for those impacted by this disease. As part of this effort, we’re inspired by the work of TD2’s Chief Development Strategist, Dr. Daniel D. Von Hoff, whose contributions to the development of therapies like gemcitabine have transformed the treatment landscape. His commitment to molecularly targeted therapies for advanced pancreatic cancer underscores the critical need for continued progress. Let’s work together to raise awareness and drive research forward. #WorldPancreaticCancerDay #PancreaticCancerResearch #OncologyInnovation

Join our Chief Medical Officer, Dr. Alan Miller MD, PhD, and Senior Director of Business Development, Parris Johnson, at #ASH2024 in San Diego! Discover how our comprehensive oncology ecosystem can support your hematologic malignancy clinical trials. Follow the link to learn more about these tailored services and schedule a meeting today! 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions

Did you see our posters at SITC 2024? If you missed them, you can still download them here! Our research highlights innovative approaches in preclinical and translational oncology: The Antitumor and Metabolomic Difference Between Male and Female Diet-Induced Obese Mice Treated With Checkpoint Inhibitors • This study examines the impact of diet-induced obesity on tumor growth, immune responses, and metabolomic profiles in murine cancer models, with notable differences between male and female mice. Download Here: https://hubs.li/Q02YCKV20 Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens • Explore the development of receptor occupancy assays for monitoring drug-target engagement, utilizing advanced flow cytometry techniques to support immunotherapy research. Download Here: https://hubs.li/Q02YCKWY0 #SITC2024 #OncologyResearch #TD2Oncology

November is Lung Cancer Awareness Month As we recognize this month, we stand with patients, families, and advocates working toward a future with better treatments and outcomes. Lung cancer remains one of the most common and challenging cancers, especially in cases with specific mutations that limit treatment options. Earlier this year at AACR 2024, TD2 presented new findings on an epigenetic-based combinatorial therapy targeting KRAS/LKB1-mutant non-small cell lung cancer (NSCLC). By combining novel HDAC inhibitors with trametinib, this approach shows potential to improve outcomes for patients with these aggressive mutations. Watch the video learn more about our research here: https://hubs.li/Q02Y9J580 #LungCancerAwareness #OncologyResearch #CancerAwareness

Check out our latest blog, where we dive into the main obstacles in radiopharmaceutical development and explore strategies for overcoming them. 🔗https://hubs.li/Q02XBW7L0 #Radiopharmaceuticals #ClinicalTrials #Oncology #CancerResearch #TD2 #Theranostics #PrecisionOncology #DrugDevelopment

Reminder for Today: Saturday Poster Presentation at SITC 2024! We’re excited to present our latest research on The Antitumor and Metabolomic Differences Between Male and Female Diet-Induced Obese Mice at the SITC Annual Meeting. Stop by abstract #1364 and speak with presenter Erin Trachet about the poster! Follow this link for more details on today’s poster: https://hubs.li/Q02XDxq50 #SITC2024 #TD2

TD2 is continuing our Friday poster presentation at SITC 2024: Design and Validation of a Model of a Receptor Occupancy Assay for a new Immunotherapy in Human Whole Blood Specimens. Stop by Abstract #201 to learn more and speak with our presenter Jennifer Stewart.

Reminder for Today: New Poster Presentation at SITC 2024! We’re excited to present our latest research on The Antitumor and Metabolomic Differences Between Male and Female Diet-Induced Obese Mice Treated with Checkpoint Inhibitors at the SITC Annual Meeting. Our findings highlight how gender and metabolic state impact therapeutic outcomes, offering new insights for optimizing immuno-oncology treatments. Follow this link for more details on today’s poster: https://hubs.li/Q02XyfRR0 #SITC2024 #ImmunoOncology #CancerResearch #PreclinicalStudies

Experiencing roadblocks in your radiopharmaceutical clinical trials? Our latest blog reviews how to navigate some of the most common challenges in the field, from managing short isotope half-lives and supply chain bottlenecks to addressing regulatory hurdles and recruitment issues. If you’re looking to overcome these obstacles and drive success in your trials, this is a must-read! Read the full blog here 🔗https://hubs.ly/Q02XnG-q0 #Radiopharmaceuticals #ClinicalTrials #Oncology #CancerResearch #TD2 #Theranostics #PrecisionOncology #DrugDevelopment

A heartfelt thank you to team TD2 for showing up for Head for the Cure, whether locally or remotely, and supporting brain cancer patients and their loved ones. Together, we contributed to the Ivy Brain Tumor Center at Barrow Neurological Center, a place that inspires hope for patients, caregivers, researchers, and the entire community. This event truly highlighted the courage, spirit, and resilience of everyone affected by brain cancer—and reminded us why the work we do at TD2 is so important. Learn more about Head for the Cure and its mission here: https://hubs.li/Q02XmkCz0 #BrainCancerAwareness #HeadfortheCure #Oncology